Molecular and Cellular Biochemistry

, Volume 224, Issue 1, pp 123–133

Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells

  • Nambi Aiyar
  • Jyoti Disa
  • Mark Pullen
  • Ponnal Nambi
Article

DOI: 10.1023/A:1011907328682

Cite this article as:
Aiyar, N., Disa, J., Pullen, M. et al. Mol Cell Biochem (2001) 224: 123. doi:10.1023/A:1011907328682

Abstract

Calcitonin gene-related peptide (CGRP) and adrenomedullin (ADM), two closely related peptides, initiate their biological responses through their interaction with calcitonin receptor-like receptor (CRLR). The CRLR receptor phenotype can be determined by coexpression of CRLR with one of the three-receptor activity modifying proteins (RAMPs). In this report, we characterized the pharmacological properties of the human or porcine CRLR with individual RAMPs transiently expressed in human embroynic kidney cell line (HEK-293). Characterization of RAMP1/human or porcine CRLR combination by radioligand binding ([125I] hαCGRP) and functional assay (activation of adenylyl cyclase) revealed the properties of CGRP receptor. Similarly characterization of RAMP2/human or porcine CRLR and RAMP3/human or porcine CRLR combination by radioligand binding ([125I]rADM) and functional assay (activation of adenylyl cyclase) revealed the properties of ADM (22–52) sensitive-ADM receptor. In addition, porcine CRLR/RAMP2 or 3 combination displayed specific high affinity [125I] hαCGRP binding also. Also, co-transfection of porcine CRLR with RAMPs provided higher expression level of the receptor than the human counterpart. Thus the present study along with earlier studies strongly support the role of RAMPs in the functional expression of specific CRLRs.

calcitonin receptor like receptor (CRLR)receptor activity modifying protein (RAMP)CGRPADMradioligand bindingadenylyl cyclase

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Nambi Aiyar
    • 1
  • Jyoti Disa
    • 1
  • Mark Pullen
    • 1
  • Ponnal Nambi
    • 1
    • 2
  1. 1.Department of Cardiovascular PharmacologyGlaxoSmithKlineKingof PrussiaUSA
  2. 2.Experimental StationP. Nambi, Leads Discovery, E 357/1122, Dupont PharmaceuticalsWilmingtonUSA